What Happened?
Cambridge, MA-based Tessera Therapeutics Promoted Jacob Rubens as Chief Innovation Officer
About the Company
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
About the Person
Jacob Rubens is Chief Innovation Officer at Tessera Therapeutics. Previously, Jacob held various senior IT leadership roles in the industry.
Info Source
News
Short Profile